Drugs / PTX-COVID19-B
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04765436 | Jan 2021 → Mar 2022 | — | Providence Therapeutics Holdings Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05175742 | Aug 2021 → Mar 2023 | — | Providence Therapeutics Holdings Inc. | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT05534048 | Feb → Jul 2023 | COVID-19 | Everest Medicines (Singapore) Pte. Ltd. | Unknown | No outcome recorded |
| Phase 3 | NCT05534035 | Feb → Apr 2023 | COVID-19 | Everest Medicines (Singapore) Pte. Ltd. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PTX-COVID19-B | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05534035 ↗ |
| Modality | Messenger RNA (mRNA) | “Therefore, a low-cost mRNA vaccine, PTX-COVID19-B, was produced and evaluated in a Phase 1 trial.” PMID 37236995 ↗ May 2023 |
| Route | Intramuscular | “Participants, 45 healthy adults 18 to 64 years of age, will receive 1 intramuscular (IM) injection of PTX-COVID19-B vaccine in doses of 16 μg, 40 μg and 100 μg on Day 1,...” NCT04765436 ↗ |